Singapore, May 8 -- Suzhou Siran Biotechnology has announced a worldwide exclusive license agreement with GSK (excluding mainland China, Hong Kong, Macau and Taiwan) for SA030, a potential first-in-disease, long-acting, small interfering RNA (siRNA) oligonucleotide in development for treatment of metabolic and vascular disease.

SA030 has recently entered phase I trials and targets activin receptor-like kinase 7 (ALK7), an established therapeutic mechanism for cardiometabolic disease. The programme represents broad clinical and market potential given unaddressed cardiometabolic risk across multiple chronic diseases.

Cardiometabolic disease is the leading cause of death in approximately 50% of patients with chronic kidney and liver diseas...